Poster Sidebar With Form
Patient-derived xenograft (PDX) models of NSCLC reflect clinical drug responses and predict effective treatments for patients
Daniel Ciznadija1, Igor Astaturov2, Haiying Cheng3, Nir Peled4, Jennifer Jaskowiak1, Angela Davies1, and David Sidransky5 1 Champions Oncology, Baltimore, USA. 2 Fox Chase Cancer Center, Philadelphia, USA. 3 Albert Einstein College of Medicine (Montefiore), New York, USA. 4 Rabin Medical Center, Tel Aviv, Israel. 5 Johns Hopkins University School of Medicine, Baltimore, USA
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality and prognosis remains poor despite the availability of numerous therapies. Integration of drug screening and sequencing in PDX models may allow for improved understanding of mechanisms of resistance (de novo and acquired), identification of biomarkers, and optimization of therapeutic strategies for NSCLC patients. In this study, we evaluated the response of NSCLC PDX models to multiple therapies and correlated responses to known clinical outcomes and molecular characteristics.